Global efforts to combat tuberculosis (TB) have saved an estimated 53 million lives since 2000 and reduced the TB mortality rate by 37%, according to the Global TB Report 2017, released by WHO today.
BioMarin Pharmaceutical announced that the U.S. Food and Drug Administration (FDA) granted its valoctocogene roxaparvovec for Hemophilia A Breakthrough Therapy Designation.
Prospects for GlaxoSmithKline’s new shingle vaccine Shingrix have been raised after US advisors recommended that it should be used instead of rival Zostavax from Merck & Co.
In the first randomized controlled trial in pediatric multiple sclerosis, fingolimod (Gilenya) significantly cut relapses compared with interferon beta-1a (Avonex), researchers reported here.
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
Coronary heart disease is a common illness of cardiovascular disease which is treated mainly through medicines, coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). Remarkably, PCI is preferable to both clinicians and patients for its short treatment course, small wound and significant therapeutic effects: doctors can use PCI to open coronary arteries that are narrowed or blocked by the buildup of atherosclerotic plaque without thoracotomy. Today, Ddu is going to share the market report of coronary stent with you.
A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
One of the biggest risk factors for vision loss is age. As people grow old, the central part of the retina can become damaged, leading patients to lose the central part of their vision in a condition called age-related macular degeneration (AMD).
AstraZeneca today announced that the US Food and Drug Administration (FDA) has approved Bydureon® BCise™ (exenatide extended-release) injectable suspension, a new formulation of Bydureon (exenatide extended-release) injectable suspension in an improved once-weekly, single-dose autoinjector device for adults with type-2 diabetes whose blood sugar remains uncontrolled on one or more oral medicines in addition to diet and exercise, to improve glycemic control.
Alexion Pharmaceuticals Inc. is set to secure even more revenue from its blockbuster drug Soliris, the most expensive drug in the world.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.